Severe hypokalemia due to a possible drug–drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin’s lymphoma

Abstract

A 60-year-old HIV-1 infected woman on antiretroviral therapy (emtricitabine/tenofovir, and ritonavir-boosted atazanavir) developed Hodgkin’s lymphoma. The patient initiated ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) chemotherapy and presented with neutropenia and severe hypokalemia. Hypokalemia was considered as part of a proximal tubular renal dysfunction, and other causes of hypokalemia were excluded. Due to suspicion of drug-–drug interactions between antiretrovirals and vinblastine, ritonavir-boosted atazanavir was switched to dolutegravir and the patient continued emtricitabine/tenofovir. In the subsequent ABVD cycles, no neutropenia or hypokalemia were observed. Vinblastine is metabolized by the hepatic P450 cytochrome isoenzyme CYP3A4, therefore, concomitant administration with protease inhibitors may increase plasma levels of vinblastine. Vinblastine is also a substrate and inhibitor of multidrug resistance-associated protein 2 (MRP2) transporter in the proximal renal tubule. Inhibition of this renal transporter could increase tenofovir renal toxicity. Our hypothesis is that the hypokalemia could be a result of a tenofovir-mediated tubular damage triggered by the increased vinblastine serum levels secondary to a CYP3A4 inhibition by ritonavir. To the best of our knowledge, this is the first report of severe hypokalemia and proximal tubular renal dysfunction as a result of a possible drug–drug interaction between vinblastine, tenofovir and ritonavir-boosted atazanavir.

Keywords

AIDS antiviral highly active antiretroviral therapy HIV toxicity renal vinblastine

Get full access to this article

View all access options for this article.

References

Uldrick

Little

. How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus. Blood 2015; 125: 1226–1235.

Bower

Palfreeman

Alfa-Wali

et al.

British HIV Association guidelines for HIV-associated malignancies 2014. HIV Med 2014; 15: 1–92.

Cingolani

Torti

Pinetti

et al.

Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin’s lymphoma. AIDS 2010; 24: 2408–2412.

Antoniou

Tseng

. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005; 44: 111–145.

El-Sheikh

Greupink

Wortelboer

et al.

Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4. Transl Res 2013; 162: 398–409.

Cirino

Kan

. Hypokalemia in HIV patients on tenofovir. AIDS 2006; 20: 1671–1673.

Gutierrez

Fulladosa

Barril

et al.

Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev 2014; 16: 199–212.

Moss

Neary

Owen

. The role of drug transporters in the kidney: lessons from tenofovir. Front Pharmacol 2014; 5: 248–248.

Salcedo

Aguayo

Zuñiga

. Syndrome of inappropriate antidiuretic hormone secretion in a patient with a Nodular Lymphocyte-Predominant Hodgkin Lymphoma. A case report and review of literature. JHOR 2015; 2: 1–6.

10.

Fraschini

Recchia

Holmes

. Syndrome of inappropriate antidiuretic hormone secretion associated with hepatic arterial infusion of vinblastine in three patients with breast cancer. Tumori 1987; 73: 513–516.